Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
MWN-AI** Summary
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), an integrated biopharmaceutical company focused on developing innovative cancer therapies, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026. The company has established a robust pipeline featuring differentiated drug candidates, including significant inhibitors targeting critical apoptotic pathway proteins like Bcl-2 and MDM2-p53, alongside advanced kinase inhibitors.
Ascentage's flagship product, Olverembatinib, holds the distinction of being the first approved third-generation BCR-ABL1 inhibitor in China, specifically designed for chronic myeloid leukemia (CML) patients with T315I mutations and those resistant to earlier treatment generations. Its inclusion in the National Reimbursement Drug List (NRDL) in China further enhances its market potential. Currently, Ascentage is advancing Olverembatinib through a globally cleared Phase III trial named POLARIS-2, targeting both newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST).
The company’s second approved therapy, Lisaftoclax, is a Bcl-2 inhibitor approved for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who failed prior systemic treatments, including BTK inhibitors. Ascentage is conducting four Phase III registrational trials for Lisaftoclax, which have received clearance from multiple regulatory bodies across the U.S. and China.
Ascentage Pharma has cultivated valuable partnerships with leading pharmaceutical companies like Takeda, AstraZeneca, and Merck, as well as prestigious research institutions, underscoring its commitment to advancing oncological research and developing therapies that address unmet medical needs. For further updates, Ascentage encourages stakeholders to visit their official website.
MWN-AI** Analysis
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is poised for significant market visibility ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2026. Given its innovative pipeline and recent regulatory approvals, Ascentage Pharma represents a compelling investment opportunity within the biopharmaceutical sector.
The firm has successfully commercialized its first product, Olverembatinib, a third-generation BCR-ABL1 inhibitor effective against chronic myeloid leukemia (CML) with T315I mutations. Its inclusion in the China National Reimbursement Drug List enhances market accessibility and positions it favorably for sustained revenue growth. Additionally, the ongoing global Phase III trials for both Olverembatinib and Lisaftoclax—its second product—underscore the company's commitment to addressing critical cancer treatment gaps.
Ascentage’s robust partnerships with leading pharmaceutical entities such as Takeda, AstraZeneca, and Merck further bolster its credibility and potential for collaborative advancements. These alliances not only improve resource allocation but also enhance its R&D capabilities, increasing the likelihood of successful drug commercialization and attracting additional investors.
The upcoming conference presentation is an excellent platform for management to discuss ACCP's milestones and future direction, potentially catalyzing stock interest. Investors should closely monitor any updates from ongoing clinical trials, as positive results could reflect favorably on the company's valuation.
However, it is important to note the inherent risks associated with pharmaceutical investments, particularly concerning clinical trial outcomes and regulatory approvals. Investors should evaluate these risks against Ascentage's growth trajectory and strong market potential.
In conclusion, Ascentage Pharma’s innovative portfolio, strategic partnerships, and upcoming visibility at a prestigious healthcare conference make it a viable consideration for investors looking to capitalize on opportunities within the oncology-focused biopharmaceutical sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for Wednesday, January 14, 2026, at 2:15 p.m. PT.
About Ascentage Pharma Group International
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key apoptotic pathway proteins, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.
Ascentage Pharma's first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the US FDA, the EMA of the EU, and China CDE.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Stella Yang
Ascentage Pharma
Stella.Yang@ascentage.com
+1 (301) 792-6286
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012
FAQ**
How is Ascentage Pharma Group ASPHF positioned to address unmet medical needs in cancer treatment compared to its competitors in Rockville, MD, and Suzhou, China?
What partnerships does Ascentage Pharma Group ASPHF have with local biotech firms in Rockville, MD, and Suzhou, China, to enhance their research and development capabilities?
What impact do the upcoming presentations and trials of Ascentage Pharma Group ASPHF at the J.P. Morgan Healthcare Conference have on investor sentiment in Rockville, MD, and Suzhou, China?
How do regulatory environments in Rockville, MD, and Suzhou, China, influence the commercialization strategy of Ascentage Pharma Group ASPHF, particularly for their innovative drug pipeline?
**MWN-AI FAQ is based on asking OpenAI questions about Ascentage Pharma Group (OTC: ASPHF).
NASDAQ: ASPHF
ASPHF Trading
178.06% G/L:
$8.48 Last:
100 Volume:
$8.48 Open:
